Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain

References

• OliveraBMRivierJClarkCDiversity of Conus neuropeptidesScience199024949662572632165278
   PubMed Web of Science ®Google Scholar
• OliveraBMMiljanichGPRamachandranJAdamsMECalcium-channel diversity and neurotransmitter release – the ω-conotoxins and ω-agatoxinsAnn Rev Biochem1994638238677979255
   PubMed Web of Science ®Google Scholar
• ChungDGaurSBellJRRamachandranJNadasdiLDetermination of disulfide bridge pattern in ω-conopeptidesInt J Pept Protein Res19954634320325
   Google Scholar
• Price-CarterMHullMSGoldenbergDPRoles of individual disulfide bonds in the stability and folding of an ω-conotoxinBiochemistry19983727985198619657699
   PubMed Web of Science ®Google Scholar
• OliveraBMConus Peptides: Biodiversity-based Discovery and ExogenomicsJ Biolog Chem2006281423117331177
   PubMed Web of Science ®Google Scholar
• TerlauHOliveraBMConus venoms: a rich source of novel ion channel-targeted peptidesPhysiol Rev2004841416814715910
   PubMed Web of Science ®Google Scholar
• MondalSBhavnaRBabuRMRamakumarSPseudo amino acid composition and multi-class support vector machines approach for conotoxin superfamily classificationJ Theor Biol2006243225226016890961
   PubMed Web of Science ®Google Scholar
• LinHLiQLPredicting conotoxin superfamily and family by using pseudo amino acid composition and modified Mahalanobis discriminantBiochem Biophys Res Comm (BBRC)2007354548551
   PubMed Web of Science ®Google Scholar
• TeichertRWJimenezECTweeVNovel conantokins from Conus parius venom are specific antagonists of N-methyl-D-aspartate receptorsJ Biol Chem200728251369053691317962189
   PubMed Web of Science ®Google Scholar
• KhooKKFengZPSmithBJStructure of the analgesic mu-conotoxin KIIIA and effects on the structure and function of disulfide deletion (dagger) (double dagger)Biochemistry2009In press
   PubMed Web of Science ®Google Scholar
• BroseWPheiferBHassenbuschSAnalgesia produced by SNX-111 in patients with morphine resistant painPresented at: 15th Annual Meeting of the American Pain SocietyNovember 14–17; 1996Washington, DC
   Google Scholar
• OliveraBMCruzLJde SantosVNeuronal calcium channel antagonists: Discrimination between calcium channel subtypes using omegaconotoxin from conus magus venomBiochemistry1987268208620902441741
   PubMed Web of Science ®Google Scholar
• MiljanichGRamachandranJAntagonists of neuronal calcium channels: Structure, function, and therapeutic implicationsAnnu Rev Pharmacol Toxicol1995357077347598513
   PubMed Web of Science ®Google Scholar
• StaatsPSYearwoodTCharapataSGIntrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: A randomized controlled trialJAMA20042911637014709577
   PubMed Web of Science ®Google Scholar
• YeagerREYoshikamiDRivierJCruzLJMiljanichGPTransmitter release from presynaptic terminals of electric organ: inhibition by the calcium channel antagonist ω Conus toxinJ Neurosci198778239023963112325
   PubMed Web of Science ®Google Scholar
• AtkinsonRAKiefferBDejaegereASirockinFLefevreJFStructural and dynamic characterization of ω-conotoxin MVIIA: the binding loop exhibits slow conformational exchangeBiochemistry200039143908391910747778
   PubMed Web of Science ®Google Scholar
• KimJITakahashiMOhtakeAWakamiyaASatoKTyr13 Is essential for the activity of ω-conotoxin MVIIA and GVIA, specific N-type calcium channel blockersBiochem Biophys Res Commun199520624494547826361
   PubMed Web of Science ®Google Scholar
• GohilKBellJRRamachandranJMiljanichGPNeuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (ω-conopeptide MVIIC)Brain Res1994653122582667982041
   PubMed Web of Science ®Google Scholar
• BowersoxSSGadboisTSinghTPettusMWangYXLutherRRSelective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic painJ Pharmacol Exp Ther19962793124312498968347
   PubMed Web of Science ®Google Scholar
• KristipatiRNádasdiLTarczy-HornochKLauKMiljanichGPRamachandranJBellJRCharacterization of the binding of ω-conopeptides to different classes of non-L-type neuronal calcium channelsMol Cell Neurosci1994532192288087420
   PubMed Web of Science ®Google Scholar
• BowersoxSSLutherRPharmacotherapeutic potential of omega conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magusToxicon19983611165116589792182
   PubMed Web of Science ®Google Scholar
• WangYXPettusMGaoDPhillipsCBowersoxSSEffects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative painPain20008423151158
   Web of Science ®Google Scholar
• ShoppGMSkovMJYakshTLSubchronic toxicity of ziconotide administered by continuous intrathecal infusion in rat and dogToxicologist (Suppl to Toxicol Sci)200478S-1 Abstract 2097
   Google Scholar
• HassenbuschSJPortenoyRKCousinsMPolyanalgesic Consensus Conference 2003: An update on the management of pain by intraspinal drug delivery–report of an expert panelJ Pain Symptom Manage200427654056315165652
   PubMed Web of Science ®Google Scholar
• YakshTLHoraisKATozierNAChronically infused intrathecal morphine in dogsAnesthesiology200399117418712826858
   PubMed Web of Science ®Google Scholar
• SkovMJBeckJCde KaterAWShoppGMNonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical classInt J Toxicol200726541142117963128
   PubMed Web of Science ®Google Scholar
• MalmbergABYakshTLEffect of continuous intrathecal infusions of mega-conoceptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in ratsPain199560183907715945
   PubMed Web of Science ®Google Scholar
• WangYXGaoDPettusMPhillipsCBowersoxSSInteractions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in ratsPain20008423271281
   Web of Science ®Google Scholar
• MiljanichGPZiconotide: neuronal calcium channel blocker for treating severe chronic painCurr Med Chem200411233029304015578997
   PubMed Web of Science ®Google Scholar
• Lyseng-WilliamsonKAPerryCZiconotideCNS Drugs200620433134116599651
   PubMed Web of Science ®Google Scholar
• WermelingDDrassMEllisDPharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patientsJ Clin Pharmacol200343662463612817525
   PubMed Web of Science ®Google Scholar
• WallaceMSZiconotide: a new nonopioid intrathecal analgesic for the treatment of chronic painExpert Rev Neurother20066101423142817078783
   PubMedGoogle Scholar
• RauckRLWallaceMSLeongMSZiconotide 301 Study GroupA randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic painJ Pain Symptom Manage200631539340616716870
   PubMed Web of Science ®Google Scholar
• NewcombRAbbruscatoTJSinghTNadasdiLDavisTPMilhanichGBioavailability of ziconotide in brain: influx from blood, stability, and diffusionPeptides200021449150110822104
   PubMed Web of Science ®Google Scholar
• www.fda.gov/medwatch/SAFETY/2007/Apr_PI/Prialt_PI.pdf
   Google Scholar
• FisherRHassenbuschSKramesEA consensus statement regarding the present suggested titration for Prialt (ziconotide) (editorial)Neuromodulation200583153154
   PubMed Web of Science ®Google Scholar
• VandaeleSFReaderTACa (2+)-sensitive and insensitive omega-conotoxin GVIA binding sites in rat brainNeuroreport199459112111248080970
   PubMed Web of Science ®Google Scholar
• WallaceMSCharapataSGFisherRIntrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trialNeuromodulation2006927586
   PubMed Web of Science ®Google Scholar
• DayROWilliamsKMOpen-label extension studies: do they provide meaningful information on the safety of new drugs?Drug Saf20073029310517253876
   PubMed Web of Science ®Google Scholar
• WallaceMSRauckRFisherRCharapataSGEllisDDissanayakeSIntrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trialAnesth Analg2008106262863718227325
   PubMed Web of Science ®Google Scholar
• WebsterLRFisherRCharapataSWallaceMSLong-term intrathecal ziconotide for chronic pain: an open-label studyJ Pain Symptom Manage2008
   PubMed Web of Science ®Google Scholar
• BennettGBurchielKBuchserEClinical guidelines for intra-spinal infusion: report of an expert panel. PolyAnalgesic Consensus Conference 2000J Pain Symptom Manage2000202S37S4310989256
   PubMed Web of Science ®Google Scholar
• DeerTKramesESHassenbuschSJPolyanalgesic Consensus Conference 2007: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert PanelNeuromodulation2007104300328
   PubMed Web of Science ®Google Scholar
• WebsterLRFakataKLCharapataSFisherRMineMOpen-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic painPain Med20089328229018366508
   PubMed Web of Science ®Google Scholar
• WallaceMSKosekPSStaatsPFisherRSchultzDMLeongMPhase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic painPain Med20089327128118366507
   PubMed Web of Science ®Google Scholar
• ShieldsDMontenegroRRagusaMChemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administrationNeuromodulation200584257263
   PubMed Web of Science ®Google Scholar
• WangYXBowersoxSSAnalgesic properties of ziconotide, a selective blocker of N-type neuronal calcium channelsCNS Drug Rev200061120
   Google Scholar
• HorvathGBrodaczBHolzer-PetscheUBlood pressure changes after intrathecal co-administration of calcium channel blockers with morphine or clonidine at the spinal levelNaunyn Schmiedebergs Arch Pharmacol2002366327027512172710
   PubMed Web of Science ®Google Scholar
• SaulinoMBurtonAWDanyoDAFrostSGlanzerJSolankiDRIntrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic and spasticity: case reportsEur J Phys Rehabil Med2009
   PubMed Web of Science ®Google Scholar
• SitaramBRTsuiMRawickiHBIamSSitaramMStability and compatibility of intrathecal admixtures containing baclofen and high concentrations of morphineInt J Pharmaceutics199715311324
   Web of Science ®Google Scholar
• AlvarezJCDe MazancourtPChartier-KastlerEDenysPDrug stability testing to support clinical feasibility investigations for intrathecal baclofen-clonidine admixtureJ Pain Symptom Manage200428326827215336339
   PubMed Web of Science ®Google Scholar
• ShieldsDMonenegroRAclanJChemical stability of admixtures combining ziconotide and bupivacaine during simulated intrathecal administrationNeuromodulation200710Suppl 115
   PubMed Web of Science ®Google Scholar
• ShieldsDMonenegroRChemical stability of ziconotide-clondine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administrationNeuromodulation200710Suppl 1611
   PubMed Web of Science ®Google Scholar
• ShieldsDMonenegroRAclanJChemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administrationNeuromodulation200710Suppl 1127
   PubMed Web of Science ®Google Scholar
• SmithHSDeerTRStaatsPSVijay SinghVSehgalNCordnerHIntrathecal Drug DeliveryPain Physician2008 Opioid Special Issue112SS89S10418443642
   PubMed Web of Science ®Google Scholar
• TrisselLATrissel’s Stability of Compounded Formulations2nd editionAPHA PublicationsWashington, DC2000
   Google Scholar
• Valia-VeraJCVillanuevaVLAsensio-SamperJMLópez-AlarcónMDde AndrésJAZiconotide: an innovative alternative for intense chronic neuropathic painRev Neurol2007451166566918050098
   PubMed Web of Science ®Google Scholar
• TairaTChronix intrathecal drug administration for the control of intractable painBrain Nerve200860550951718516973
   PubMedGoogle Scholar
• WermelingDPBergerJRZiconotide infusion for severe chronic pain: case series of patients with neuropathic painPharmacotherapy200626339540216503720
   PubMed Web of Science ®Google Scholar
• Stanton-HicksMKapuralLAn effective treatment of severe complex regional pain syndrome type 1 in a child using high doses of intrathecal ziconotideJ Pain Symptom Manage200632650951117157748
   PubMed Web of Science ®Google Scholar